Swiss biopharmaceutical company Prexton Therapeutics has reported positive results of its Phase I clinical trial of PXT002331 to treat Parkinson’s disease (PD).
PXT002331 has been developed as a metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) indicated to treat PD.
Parkinson's disease is a chronic and progressive neurological disorder, triggering symptoms such as tremors, limb stiffness, slow movement and difficulties with posture and balance.
Prexton has adopted an approach to treat PD that stimulates a compensatory neuronal system, which is believed to address all symptoms caused by the disease.
The Phase I trial was a randomised, double-blind, placebo controlled, single and multiple ascending dose study conducted on humans for the first time and involving 64 healthy volunteers.
It was intended to test the safety and tolerability of the orally administered PXT002331.
Results suggested the tolerability and safety of PXT002331 in treating Parkinson’s disease.
Prexton Therapeutics CEO Francois Conquet said: "We are very happy with the completion of the first clinical trial with our lead compound PXT002331, which is the first mGluR4 PAM ever to enter a clinical phase. This is an important step for Prexton.
“This achievement ensures Prexton is in a solid position for a successful clinical development of PXT002331 as a novel treatment for Parkinson’s disease and we look forward to moving in that direction.”
Preclinical data also suggested the efficacy of the compound to reduce motor complications by modulating glutamate over activity in the central nervous system of Parkinson patients.
The company is planning to conduct a Phase II trial for Parkinson’s disease patients next year.